Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Radiation Therapy

Therapeutic area intelligence for Radiation Therapy with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Large Tumors →

Recent signals(6)

ClinicalAugust 2, 2026

Study on Liver Volume Variation Impact on SBRT Planning for Abdominal Malignancies

A prospective study will investigate the impact of liver volume variations on SBRT planning for upper abdominal malignancies.

ClinicalJuly 31, 2026

Phase I Trial Compares Proton vs. IMRT for Endometrial and Cervical Cancer

The trial evaluates side effects of proton therapy versus intensity modulated radiation therapy in post-surgical patients.

ClinicalJuly 30, 2026

Duke University Trials Lattice Radiation Therapy for Large Tumors

Duke University is investigating Lattice Radiation Therapy (LRT) in combination with palliative radiation for large tumors.

ClinicalJune 26, 2026

PREEMPT Trial Evaluates Radiation Therapy for High-Risk Asymptomatic Bone Metastases

The PREEMPT trial is assessing the efficacy of adding radiation therapy to usual treatment for patients with asymptomatic high-risk bone metastases.

ClinicalJune 22, 2026

Phase 2 Study on Single Fraction Interstitial Brachytherapy for Breast Cancer Safety

A phase 2 study is assessing the safety of single fraction interstitial brachytherapy for breast cancer.

ClinicalJune 13, 2026

Trial on MRI-guided SBRT for Liver Metastases Aims to Establish Safe Dose Levels

A clinical trial is underway to determine the maximum tolerated dose of MRI-guided SBRT for liver metastases.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.